LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Advantages == Although fluorescent dyes may not have the same sensitivity as radioactive probes, they are able to show real-time activity of molecules in action. Moreover, radiation and appropriate handling is no longer a concern. With the development of fluorescent tagging, fluorescence microscopy has allowed the visualization of specific proteins in both fixed and live cell images. Localization of specific proteins has led to important concepts in cellular biology such as the functions of distinct groups of proteins in cellular membranes and organelles. In live cell imaging, fluorescent tags enable movements of proteins and their interactions to be monitored. Latest advances in methods involving fluorescent tags have led to the visualization of mRNA and its localization within various organisms. Live cell imaging of RNA can be achieved by introducing synthesized RNA that is chemically coupled with a fluorescent tag into living cells by microinjection. This technique was used to show how the oskar mRNA in the Drosophila embryo localizes to the posterior region of the oocyte.
The three substrates of this enzyme are (S)-lactaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-lactic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-lactaldehyde:NAD+ oxidoreductase. Other names in common use include L-lactaldehyde:NAD+ oxidoreductase, and nicotinamide adenine dinucleotide (NAD+)-linked dehydrogenase. This enzyme participates in pyruvate metabolism.
Xanthoria parietina is a common and widespread lichen-forming fungus in the family Teloschistaceae. Commonly known as the yellow wall lichen, common orange lichen, or maritime sunburst lichen, this leafy lichen is known for its vibrant yellow to orange coloration and environmental adaptability. First described by Carl Linnaeus in 1753, it has become one of the most thoroughly studied lichens, contributing significantly to scientific understanding of lichen biology. Unlike many lichens that are sensitive to pollution, X. parietina grows in diverse habitats—including coastal rocks, urban walls, and tree bark—even in areas with high levels of air pollution and excess nitrogen. Its structure consists of small, overlapping lobes that typically measure less than 8 cm (3+1⁄8 in) across, with coloration that varies from bright orange in sun-exposed locations to greenish-yellow in shaded environments. The lichen represents a symbiotic partnership between a fungus and green algae of the genus Trebouxia. Its distinctive orange-yellow color comes from parietin, an anthraquinone pigment that accumulates in the outer cortex and serves as a natural sunscreen, protecting the algal partner from excessive light and ultraviolet radiation. Unlike many lichens that reproduce through specialized vegetative structures, X. parietina primarily relies on sexual reproduction through cup-shaped fruiting bodies (apothecia), each of which can release up to 50 spores per minute under humid conditions.
Sibabrata Mukhopadhyay, Mumu Chakraborty, Arun Bandyopadhyay, Dipak Kar, Tanima Banerjee, Aditya Konar, Debaprasad Jana, Siddhartha Roy, Santu Bandyopadhyay, Balram Ghosh, Mabalirajan Ulaganathan, Rakesh Johri, Subhash Sharma, Gurdarshan Singh, Bholanath Paul, Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety (August 2013). "Method for treatment of bronchial asthma (Patent US8519154B2)". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) Sujoy K Das Gupta, Abhik Saha, Archana Sharma, Siddhartha Roy, Bhabatarak Bhattacharya (January 2012). "Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis (Patent 7569537)". Retrieved 15 October 2016.{{cite web}}: CS1 maint: multiple names: authors list (link) S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U. Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. B. Chakraborty, I. C. Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, Sudeshna Chowdhury (January 2012). "Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (WO Patent 2,012,140,574)". doi:10.13140/RG.2.1.2784.6488. Retrieved 15 October 2016. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) 1st S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U.
Sources: en.wikipedia.org
Stansbury ran unopposed in the 2018 Democratic primary for the 28th district of the New Mexico House of Representatives. In the general election, she defeated Republican incumbent Jimmie C. Hall, who had held the seat for seven terms. Stansbury was again unopposed in the 2020 primary. She defeated Republican Thomas R. Stull and Libertarian Robert Vaillancourt in the general election. In the House, Stansbury introduced legislation to improve the energy conservation and water resource management of the state of New Mexico. She served as the vice chair of the Energy, Environment, & Natural Resources Committee. Upon Stansbury's 2021 resignation from the state legislature in order to run to represent New Mexico in the U.S. House of Representatives, the Bernalillo County Commission appointed Pamelya Herndon as her replacement.
=== Pseudohalogens === The character 氯 ( lǜ, "chlorine") may on occasion mean Cl (one atom), or the bonded pair Cl2 (the molecule, the usual form of chlorine). Likewise in describing pseudohalogens, 氰 (qíng) may on occasion mean a single CN− cyanide ion (e.g. as in 氰化鉀 (qínghuàjiǎ, potassium cyanide, literally "cyanide-ion transform potassium"), or the bonded pair (CN)2 or NCCN ("cyanogen"). The similar (not identical) character 腈 (jīng) means "nitrile".
Rice (1932–2024), physical chemist Ellen Swallow Richards (1842–1911), industrial and environmental chemist Theodore William Richards (1868–1928), 1914 Nobel Prize in Chemistry Wim Richter (1946–2019), South Africa Jeremias Benjamin Richter (1762–1807), German chemist, first used the term stoichiometry Nikolaus Riehl (1901–1990), German chemist Andrés Manuel del Río (1764–1849), Spanish-Mexican geochemist, discovered vanadium Robert Robinson (1886–1975), British chemist, 1947 Nobel Prize in Chemistry Pierre Jean Robiquet (1780–1840), French chemist, discovered caffeine, alizarin, cantharidin Hillar Rootare (1928–2008), Estonian-American physical chemist Irwin Rose (1926–2015), 2004 Nobel Prize in Chemistry Guillaume-François Rouelle (1703–1770), French chemist Hilaire-Marin Rouelle (1718–1779), French chemist Frank Sherwood Rowland (1927–2012), 1995 Nobel Prize in Chemistry Daniel Rutherford (1749–1819), Scottish chemist Ernest Rutherford (1871–1937), New Zealand born chemist and nuclear physicist. Discovered the proton. Nobel Prize in Chemistry 1908 Leopold Ruzicka (Lavoslav Ružička) (1887–1976), 1939 Nobel Prize in Chemistry
Sources: en.wikipedia.org
=== Iran === Iran has been an important source of turquoise for at least 2,000 years. It was initially named by Iranians "pērōzah" meaning "victory", and later the Arabs called it "fayrūzah", which is pronounced in Modern Persian as "fīrūzeh". In Iranian architecture, the blue turquoise was used to cover the domes of palaces because its intense blue colour was also a symbol of heaven on earth.
=== Various affinity media === Many different affinity media exist for a variety of possible uses. Briefly, they are (generalized) activated/functionalized that work as a functional spacer, support matrix, and eliminates handling of toxic reagents. Amino acid media is used with a variety of serum proteins, proteins, peptides, and enzymes, as well as rRNA and dsDNA. Avidin biotin media is used in the purification process of biotin/avidin and their derivatives. Carbohydrate bonding is most often used with glycoproteins or any other carbohydrate-containing substance; carbohydrate is used with lectins, glycoproteins, or any other carbohydrate metabolite protein. Dye ligand media is nonspecific but mimics biological substrates and proteins. Glutathione is useful for separation of GST tagged recombinant proteins. Heparin is a generalized affinity ligand, and it is most useful for separation of plasma coagulation proteins, along with nucleic acid enzymes and lipases Hydrophobic interaction media are most commonly used to target free carboxyl groups and proteins. Immunoaffinity media (detailed below) utilizes antigens' and antibodies' high specificity to separate; immobilized metal affinity chromatography is detailed further below and uses interactions between metal ions and proteins (usually specially tagged) to separate; nucleotide/coenzyme that works to separate dehydrogenases, kinases, and transaminases. Nucleic acids function to trap mRNA, DNA, rRNA, and other nucleic acids/oligonucleotides. Protein A/G method is used to purify immunoglobulins.
There are several GLP-1 receptor agonists approved in the EU to treat diabetes and weight management. Kayshild is the first GLP-1 medicine approved for this indication. In May 2026, the CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorization for the medicinal product Wegovy. The marketing authorization holder for this medicinal product is Novo Nordisk A/S. The CHMP adopted a new pharmaceutical form associated with a new route of administration, tablets for oral use, in four new strengths (1.5 mg, 4 mg, 9 mg and 25 mg).
=== Biotic Theory === Most contemporary research into the origin of homochirality focuses on identifying abiotic mechanisms for chiral symmetry-breaking, amplification, and propagation/transmission that could have occurred during prebiotic synthesis of biomolecule precursors or during primitive replication/polymerization. Some early theories of biological homochirality in the 1950s suggested that homochiral biopolymers of both enantiomeric forms (e.g., both D-RNA and L-RNA) could have been present in the prebiotic Earth, and that polymers of the canonical enantiomeric forms were selected for due to improved chemical function. As an extension of this idea, it was also proposed that lifeforms containing both enantiomeric forms of molecular machinery could have arisen independently, and that evolution by natural selection eventually led to the complete dominance of one enantiomeric lifeform. This purely biotic theory is difficult to assess experimentally, and is not widely accepted or discussed in the scientific community.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.